Validation of an HPLC-CAD Method for Determination of Lipid Content in LNP-Encapsulated COVID-19 mRNA Vaccines
Xiaojuan Yu, Chuanfei Yu, Xiaohong Wu, Yu Cui, Xiaoda Liu, Yan Jin, Yuhua Li, Lan Wang
Abstract
Lipid nanoparticles (LNPs) are widely used as delivery systems for mRNA vaccines. The stability and bilayer fluidity of LNPs are determined by the properties and contents of the various lipids used in the formulation system, and the delivery efficiency of LNPs largely depends on the lipid composition. For the quality control of such vaccines, here we developed and validated an HPLC-CAD method to identify and determine the contents of four lipids in an LNP-encapsulated COVID-19 mRNA vaccine to support lipid analysis for the development of new drugs and vaccines.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)ChemistryHigh-performance liquid chromatographyBilayerChromatographyBiochemistryMedicineMembraneInfectious disease (medical specialty)PathologyDiseaseRNA Interference and Gene DeliveryImmunotherapy and Immune ResponsesSARS-CoV-2 and COVID-19 Research